Novartis headquarters in Basel
|Predecessor||Ciba-Geigy, Sandoz (via merger)|
|Products||Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...)|
|Revenue||US$51.900 billion (2018)|
|US$8.169 billion (2018)|
|US$12.614 billion (2018)|
|Total assets||US$145.563 billion (2018)|
|Total equity||US$78.692 billion (2018)|
Number of employees
Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.
In 1996, Ciba-Geigy merged with Sandoz; the pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA).
- 1 Corporate structure
- 2 Place in its market segments
- 3 History
- 4 Research
- 5 Products
- 6 Controversies and criticism
- 7 See also
- 8 References
- 9 Further reading
- 10 External links
Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group. Novartis AG owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group.
Novartis's businesses are divided into three operating divisions: Innovative Medicines, Sandoz (generics) and Alcon (eyecare). In April 2019, Novartis spun off Alcon into a separate company. The Innovative Medicines division comprises two business units: Novartis Pharmaceuticals and Novartis Oncology.:150  Novartis operates directly through subsidiaries, each of which fall under one of the divisions, and that Novartis categorizes as fulfilling one or more of the following functions: Holding/Finance, Sales, Production, and Research :251–253
Novartis AG also holds 33.3% of the shares of Roche however, it does not exercise control over Roche. Novartis also has two significant license agreements with Genentech, a Roche subsidiary. One agreement is for Lucentis; the other is for Xolair.:239[better source needed]
In 2014, Novartis established a center in Hyderabad, India, in order to offshore several of its R&D, clinical development, medical writing and administrative functions. The center supports the drug major's operations in the pharmaceuticals (Novartis), eye care (Alcon) and generic drugs segments (Sandoz).
Place in its market segments
This section needs to be updated.September 2018)(
Overall, Novartis was the world's second largest pharmaceutical company in 2011.
Alcon: At the time Novartis bought Alcon, they had annual sales of $6.5 billion and a net income of $2 billion. In April 2019, Novartis completed the spin-off of Alcon as a separate commercial entity.
Sandoz: As of 2013[update], Sandoz has been recognized as the world's second-largest generic drug company. Sandoz' biosimilars lead its field, getting the first biosimilar approvals in the EU. In 2018, Sandoz reported US$9.9 billion in net sales.
Vaccines and Diagnostics Division: In 2013, Novartis announced it was considering selling the vaccines and diagnostics division off. This sale was completed in late 2015, and the division was integrated into CSL's BioCSL operation, with the combined entity trading as Seqirus. In 2018, Novartis sold its consumer healthcare joint venture vaccines division to GlaxoSmithKline for US$13.0 billion.
Consumer: Novartis is not a leader in the over-the-counter or animal health segments; its leading OTC brands are Excedrin and Theraflu, but sales have been slowed by problems at its key US manufacturing plant.
For the fiscal year 2018, Novartis reported earnings of US$12.6 billion, with an annual revenue of US$53.2 billion, an increase of 6.05% over the previous fiscal cycle. Novartis shares traded at over $91 per share, and its market capitalization was valued at over US$209.7B billion in February 2019.
in mil. USD$
in mil. USD$
|Price per Share
Novartis was created in 1996 from the merger of Ciba-Geigy and Sandoz Laboratories, both Swiss companies.
Ciba-Geigy was formed in 1970 by the merger of J. R. Geigy Ltd (founded in Basel in 1758) and CIBA (founded in Basel in 1859).
Ciba began in 1859, when Alexander Clavel (1805–1873) took up the production of fuchsine in his factory for silk-dyeing works in Basel. By 1873, he sold his dye factory to the company Bindschedler and Busch. In 1884, Bindschedler and Busch was transformed into a joint-stock company named "Gesellschaft für Chemische Industrie Basel" (Company for Chemical Industry Basel). The acronym, CIBA, was adopted as the company's name in 1945.
The foundation for Geigy was established in 1857, when Johann Rudolf Geigy-Merian (1830–1917) and Johann Muller-Pack acquired a site in Basel, where they built a dyewood mill and a dye extraction plant. Two years later, they began the production of synthetic fuchsine. In 1901, they formed the public limited company Geigy, and the name of the company was changed to J. R. Geigy Ltd in 1914.
Mid 1990s Controversy
In the mid-1990s, state and federal health and environmental agencies identified an increased incidence of childhood cancers in Toms River from the 1970–1995 period. Multiple investigations by state and federal environmental and health agencies indicated that the likely source of the increased cancer risk was contamination from Toms River Chemical Plant (then operated by Ciba-Geigy), which had been in operation since 1952. The area was designated a United States Environmental Protection Agency Superfund site in 1983 after an underground plume of toxic chemicals was identified. The following year, a discharge pipe was shut down after a sinkhole at the corner of Bay Avenue and Vaughn Avenue revealed that it had been leaking. The plant ceased operation in 1996. A follow up study from the 1996–2000 period indicated that while there were more cancer cases than expected, rates had significantly fallen and the difference was statistically insignificant compared to normal statewide cancer rates Since 1996, the Toms River water system has been subject to the most stringent water testing in the state and is considered safe for consumption. Dan Fagin's Toms River: A Story of Science and Salvation, the 2014 Pulitzer Prize winning book, examined the issue of industrial pollution in detail
Before the 1996 merger with Ciba-Geigy to form Novartis, Sandoz Pharmaceuticals (Sandoz AG) was a pharmaceutical company headquartered in Basel, Switzerland (as was Ciba-Geigy), and was best known for developing drugs such as Sandimmune for organ transplantation, the antipsychotic Clozaril, Mellaril Tablets and Serentil Tablets for treating psychiatric disorders, and Cafergot Tablets and Torecan Suppositories for treating migraine headaches.
The Chemiefirma Kern und Sandoz ("Kern and Sandoz Chemistry Firm") was founded in 1886 by Alfred Kern (1850–1893) and Edouard Sandoz (1853–1928). The first dyes manufactured by them were alizarinblue and auramine. After Kern's death, the partnership became the corporation Chemische Fabrik vormals Sandoz in 1895. The company began producing the fever-reducing drug antipyrin in the same year. In 1899, the company began producing the sugar substitute saccharin. Further pharmaceutical research began in 1917 under Arthur Stoll (1887–1971), who is the founder of Sandoz's pharmaceutical department in 1917. In 1918, Arthur Stoll isolated ergotamine from ergot; the substance was eventually used to treat migraine and headaches and was introduced under the trade name Gynergen in 1921.
Between the World Wars, Gynergen (1921) and Calcium-Sandoz (1929) were brought to market. Sandoz also produced chemicals for textiles, paper, and leather, beginning in 1929. In 1939, the company began producing agricultural chemicals.
The psychedelic effects of lysergic acid diethylamide (LSD) were discovered at the Sandoz laboratories in 1943 by Arthur Stoll and Albert Hofmann. Sandoz began clinical trials and marketed the substance, from 1947 through the mid-1960s, under the name Delysid as a psychiatric drug, thought useful for treating a wide variety of mental ailments, ranging from alcoholism to sexual deviancy. Sandoz suggested in its marketing literature that psychiatrists take LSD themselves, to gain a better subjective understanding of the schizophrenic experience, and many did exactly that and so did other scientific researchers. The Sandoz product received mass publicity as early as 1954, in a Time Magazine feature. Research on LSD peaked in the 1950s and early 1960s. Sandoz withdrew the drug from the market in 1965. The drug became a cultural novelty of the 1960s after psychologist Timothy Leary at Harvard University began to promote its use for recreational and spiritual experiences among the general public.
Sandoz opened its first foreign offices in 1964. In 1967, Sandoz merged with Wander AG (known for Ovomaltine and Isostar). Sandoz acquired the companies Delmark, Wasabröd (a Swedish manufacturer of crisp bread), and Gerber Products Company (a baby food company). On 1 November 1986, a fire broke out in a production plant storage room, which led to the Sandoz chemical spill and a large amount of pesticide being released into the upper Rhine river. This exposure killed many fish and other aquatic life. In 1995, Sandoz spun off its specialty chemicals business to form Clariant. In 1997, Clariant merged with the specialty chemicals business that was spun off from Hoechst AG in Germany.
In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were spun off as independent companies. Notably, Ciba Specialty Chemicals was spun out as an independent company, and Sandoz's Master Builders Technologies, a producer of chemicals for the construction industry, was sold off to SKW Trostberg A.G., a subsidiary of the German energy company VIAG, while its North American corn herbicide business was sold off to the German chemical maker BASF.
In 1998, the company entered into a biotechnology licensing agreement with the University of California at Berkeley Department of Plant and Microbial Biology. Critics of the agreement expressed concern over prospects that the agreement would diminish academic objectivity, or lead to the commercialization of genetically modified plants. The agreement expired in 2003.
2000 to 2010
In 2003, Novartis organized all its generics businesses into one division, and merged some of its subsidiaries into one company, reusing the predecessor brand name of Sandoz.
In 2005, Novartis expanded its subsidiary Sandoz significantly through the US$8.29 billion acquisition of Hexal, one of Germany's leading generic drug companies, and Eon Labs, a fast-growing United States generic pharmaceutical company.
In 2006, Novartis acquired the California-based Chiron Corporation. Chiron had been divided into three units: Chiron Vaccines, Chiron Blood Testing, and Chiron BioPharmaceuticals. The biopharmaceutical unit was integrated into Novartis Pharmaceuticals, while the vaccines and blood testing units were made into a new Novartis Vaccines and Diagnostics division. Also in 2006, Sandoz became the first company to have a biosimilar drug approved in Europe with its recombinant human growth hormone drug.
In 2009, Novartis reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the group's limited presence in this fast-growing market segment. This proposed acquisition will require government and regulatory approvals in China.
In 2010, Novartis offered to pay US$39.3 billion to fully acquire Alcon, the world's largest eye-care company, including a majority stake held by Nestlé. Novartis had bought 25% of Alcon in 2008. Novartis created a new division and called it Alcon, under which it placed its CIBA VISION subsidiary and Novartis Ophthalmics, which became the second-largest division of Novartis. The total cost for Alcon amounted to $60 billion. 
In 2011, Novartis acquired the medical laboratory diagnostics company Genoptix to "serve as a strong foundation for our (Novartis') individualized treatment programs".
In 2012, the Company cut ~2000 positions in the United States, most in sales, in response to anticipated revenue downturns from the hypertension drug Diovan, which was losing patent protection, and the realization that the anticipated successor to Diovan, Rasilez, was failing in clinical trials. The 2012 personnel reductions follow ~2000 cut positions in Switzerland and the United States in 2011, ~1400 cut positions in the United States in 2010, and a reduction of "thousands" and several site closures in previous years. Also in 2012, Novartis became the biggest manufacturer of generic skin care medicine, after agreeing to buy Fougera Pharmaceuticals for $1.525 billion in cash.
In 2013, the Indian Supreme Court issued a decision rejecting Novartis' patent application in India on the final form of Gleevec, Novartis's cancer drug; the case caused great controversy. In 2013, Novartis was sued again by the US government, this time for allegedly bribing doctors for a decade so that their patients are steered towards the company's drugs.
In January 2014, Novartis announced plans to cut 500 jobs from its pharmaceuticals division. In February 2014, Novartis announced that it acquired CoStim Pharmaceuticals. In May 2014, Novartis bought the rights to market Ophthotech's Fovista (an anti-PDGF aptamer, also being investigated for use in combination with anti-VEGF treatments) outside the United States for up to $1 billion. Novartis will acquire exclusive rights to market the eye drug outside of America while retaining US marketing rights. The company agreed to pay Ophthotech $200 million upfront, and $130 million in milestone payments relating to Phase III trials. Ophthotech is also eligible to receive up to $300 million dependent upon future marketing approval milestones outside of America and up to $400 million relating to sales milestones. In September 2014, Ophthotech received its first $50 million phase III trial milestone payment from Novartis. In April 2014, Novartis announced that it would acquire GlaxoSmithKline's cancer drug business for $16 billion as well as selling its vaccines business to GlaxoSmithKline for $7.1 billion. In August 2014 Genetic Engineering & Biotechnology News reported that Novartis had acquired a 15% stake in Gamida Cell for $35 million, with the option to purchase the whole company for approximately $165 million. In October 2014, Novartis announced its intention to sell its influenza vaccine business (inclusive of its development pipeline), subject to regulatory approval, to CSL for $275 million.
In March 2015, the company announced BioPharma had completed its acquisition of two Phase III cancer-drug candidates; the MEK inhibitor binimetinib (MEK 162) and the BRAF inhibitor encorafenib (LGX818), for $85 million. Further, the company sold its RNAi portfolio to Arrowhead Research for $10 million and $25 million in stock. In June, the company announced it would acquire Spinifex Pharmaceuticals for more than $200 million. In August, the company acquired the remaining rights to the CD20 monoclonal antibody Ofatumumab from GlaxoSmithKline for up to $1 billion. In October the company acquired Admune Therapeutics for an undisclosed sum, as well as licensing PBF-509, an adenosine A2A receptor antagonist which is in Phase I clinical trials for non-small cell lung cancer, from Palobiofarma.
In November 2016, the company announced it would acquire Selexys Pharmaceuticals for $665 million. In December, the company acquired Encore Vision, gaining the company's principle compound, EV06, is a first-in-class topical therapy for presbyopia. In December Novartis acquired Ziarco Group Limited, bolstering its presence in eczema treatments.
In late October 2017, Reuters announced that Novartis would acquire Advanced Accelerator Applications for $3.9 billion, paying $41 per ordinary share and $82 per American depositary share representing a 47 percent premium.
In March 2018, GlaxoSmithKline announced that it has reached an agreement with Novartis to acquire Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion). In April of the same year, the business utilised some of the proceeds from the aforementioned GlaxoSmithKline deal to acquire Avexis for $218 per share or $8.7 billion in total, gaining the lead compound AVXS-101 used to treat spinal muscular atrophy. In August 2018, Novartis signed a deal with Laekna-a Shanghai-based pharmaceutical company for its two clinical-stage cancer drugs. Novartis gave Laekna the exclusive international rights for the drugs that are oral pan-Akt kinase inhibitors namely; afuresertib (ASB138) and uprosertib (UPB795). In mid-October, the company announced it would acquire Endocyte Inc for $2.1 billion ($24 per share) merging it with a newly created subsidiary. Endocyte will bolster Novartis' offering in its radiopharmaceuticals business, with Endocyte's first in class candidate 177Lu-PSMA-617 being targeted against metastatic castration-resistant prostate cancer. In late December the company announced it would acquire France-based contract manufacturer, CellforCure from LFB - boosting its capacity to produce cell and gene therapies.
On 9 April 2019, Novartis announced that it had completed the spin-off of Alcon as a separate commercial entity. Alcon was listed on the SIX exchange in Switzerland and NYSE exchange in the USA. Novartis announced during late 2019 a five-year artificial intelligence "alliance" with Microsoft. The companies aim to create applications for "Microsoft's AI capabilities", in turn improving the other's drug development processes. Microsoft seeks to "test AI products it is already working on in 'real-life' situations". The deal will pursue solutions for "organizing and using" data generated from Novartis' laboratory experiments, clinical trials, and manufacturing plants. It will also look at improving manufacturing of Chimeric antigen receptor T cell (CAR T cells). Finally, the deal "will also apply AI to generative chemistry to enhance drug design". In November 2019, Sandoz announced it would acquire the Japanese business of Aspen Global inc for €300 million (around $330 million), boosting the business' presence in Asia. In late November 2019, the business announced it would acquire The Medicines Company for US$9.7 billion ($85 per share) in order to acquire amongst other assets, the cholesterol lowering therapy; inclisiran.
The company's global research operations, called "Novartis Institutes for BioMedical Research (NIBR)" have their global headquarters in Cambridge, Massachusetts, United States. Two research institutes reside within NIBR that focus on diseases in the developing world: Novartis Institute for Tropical Diseases, which works on tuberculosis, dengue, and malaria, and Novartis Vaccines Institute for Global Health, which works on salmonella typhi (typhoid fever) and shigella.
Novartis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox project. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.
Novartis is working with Science 37 in order to allow video based telemedicine visits instead of physical traveling to clinics for patients. It is planning for ten clinical trials over three years using mobile technology to help free patients from burdensome hospital trips.
|Name||Indication(s) or drug type/class||Sales US$1,000,000||Sales year||% Change||Notes|
|Aclasta/Reclast (zoledronic acid)||Osteoporosis||590||2012||−4%|
|Afinitor/Certican/Zortress (everolimus)||Prevention of transplant rejection, various cancers||797||2012||80%|
|Anafranil (clomipramine)||Major depressive disorder, obsessive-compulsive disorder|
|Arcapta Neohaler/Onbrez Breezhaler (indacaterol)||COPD|
|Clozaril/Leponex (clozapine)||Treatment-resistant schizophrenia|
|Coartem/Riamet (artemether/lumefantrine)||Malaria (uncomplicated)|
|Comtan (entacapone)||Parkinson's disease||530||2012||−14%|
|Entresto (sacubitril/valsartan)||Heart failure|
|Eucreas/Galvus Met (vildagliptin/metformin)||Diabetes mellitus type 2|
|Exelon Patch (rivastigmine)||Alzheimer's disease||1,050||2012||−2%|
|Exjade (deferasirox)||Chronic iron overload||870||2012||2%||Manufactured as tablets for oral suspension; tablets for oral use are marketed under the brand name Jadenu|
|Famvir (famciclovir)||Herpes zoster and other Herpesvirus infection|
|Femara (letrozole)||Breast cancer||438||2012||−52%|
|Focalin (dexmethylphenidate)||ADHD||First US generics of Focalin became available in 2007 Focalin XR became available in 2012.|
|Foradil/Foradile (formoterol)||Asthma, COPD|
|Galvus (vildagliptin)||Diabetes mellitus type 2||910||2012||39%|
|Gilenya (fingolimod)||Multiple sclerosis||1,195||2012||142%|
|Gleevec/Glivec (imatinib)||Oncology, Chronic myelogenous leukemia||4,675||2012||0%|
|Ilaris (canakinumab)||Cryopyrin-associated periodic syndrome|
|Jadenu (deferasirox)||Chronic iron overload||Deferasirox tablets for oral use—a new formulation of Exjade (which comes in tablets for oral suspension)|
|Jakavi/Jakafi (ruxolitinib)||Myelofibrosis (of intermediate to high risk)|
|Kymriah (tisagenlecleucel)||Acute lymphoblastic leukemia|
|Lamisil (terbinafine)||Fungal infections|
|Lucentis (ranibizumab)||Age-related macular degeneration||2,398||2012||17%|
|Ludiomil (maprotiline)||Major depressive disorder|
|Mayzent (siponimod)||Treatment for secondary progressive multiple sclerosis (SPMS)||FDA approved March 26, 2019 |
|Myfortic (mycophenolic acid)||Prevention of transplant rejection||579||2012||12%|
|Navoban (tropisetron)||Chemotherapy-induced nausea and vomiting|
|Odomzo (sonidegib)||Locally advanced basal cell carcinoma|
|Sandimmune/Neoral (ciclosporin)||Prevention of transplant rejection||821||2012||−9%|
|Sertraline Sandoz (sertraline hydrochloride)||Depression, obsessive-compulsive disorder, panic disorder||Generic form of sertraline.|
|Signifor (pasireotide)||Cushing's disease|
|Simulect (basiliximab)||Prevention of transplant rejection|
|Spersallerg (antazoline/tetrahydrozoline)||Allergic conjunctivitis|
|Stalevo (carbidopa/levodopa/entacapone)||Parkinson's disease|
|Tasigna (nilotinib)||Chronic myelogenous leukemia (first-line treatment)||998||2012||39%||NICE formulary approval, January 2012|
|Tegretol (carbamazepine)||Epilepsy, bipolar disorder||413||2007||6%|
|Termalgin (paracetamol)||Fever, mild pain|
|Tobi (tobramycin)||Prevention of Pseudomonas aeruginosa infection in cystic fibrosis||350 (US only)||2012||Teva introduced generic in the US in 2013|
|Tofranil (imipramine)||Major depressive disorder, enuresis|
|Trileptal (oxcarbazepine)||Epilepsy, bipolar disorder||690 (US only)||2007||Teva introduced generic in 2008|
|Tyzeca/Sebivo (telbivudine)||Chronic hepatitis B|
|Visudyne (verteporfin)||Age-related macular degeneration (wet form)|
|Voltaren (diclofenac)||Acute pain, inflammatory disorders (such as rheumatoid arthritis)||759 (excl. OTC)||2012||−4%|
|Zometa (zoledronic acid)||Prevention of bone fractures in cancer patients||1,288||2012||−13%|
|Xolair (omalizumab)||Moderate-to-severe asthma not controlled by inhaled steroids
Chronic idiopathic urticaria
|Zaditen (ketotifen)||Asthma, allergic conjunctivitis|
- Bialcol Alcohol
- Buckley's cold and cough formula
- Comtrex cold and cough
- Doan's pain relief
- Keri skin care
- Lamisil foot care
- Lipactin herpes symptomatic treatment
- Quinvaxem (Pentavalent vaccine)
- Prevacid 24HR
In January 2009, the United States Department of Health and Human Services awarded Novartis a $486 million contract for construction of the first US plant to produce cell-based influenza vaccine, to be located in Holly Springs, North Carolina. The stated goal of this program is the capability of producing 150,000,000 doses of pandemic vaccine within six months of declaring a flu pandemic.
In April 2014, Novartis divested its consumer health section with $3,5 billion worth of assets into a new joint venture with GlaxoSmithkline, named GSK Consumer Healthcare, of which Novartis will hold a 36,5% stake. In March 2018, GSK announced that it has reached an agreement with Novartis to acquire Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).
- Interceptor (Milbemycin oxime), oral worm control product
- Sentinel Flavor Tabs (Milbemycin oxime, Lufenuron), oral flea control product
- Deramaxx (Deracoxib), oral treatment for pain and inflammation from osteoarthritis in dogs
- Capstar (Nitenpyram), oral tablet for flea control
- Milbemax (Milbemycin oxime, Praziquantel), oral worm treatment
- Program (Lufenuron), oral tablet for flea control
- Acatalk Duostar (Fluazuron, Ivermectin), tick control for cattle
- CLiK (Dicyclanil), blowfly control for sheep
- Denagard (Tiamulin), antibiotic for the treatment of swine dysentery associated with Brachyspira (formerly Serpulina or Treponema)
- Fasinex (Triclabendazole), oral drench for cattle that is used for the treatment and control of all three stages of liver fluke
- ViraShield, For use in healthy cattle, including pregnant cows and heifers, as an aid in the prevention of disease caused by infectious bovine rhinotracheitis (IBR), bovine virus diarrhoea (BVD Type 1 and BVD Type 2), parainfluenza Type 3 (PI3), and bovine respiratory syncytial (BRSV) viruses
Bioprotection (insect and rodent control)
- Actara (Thiamenthoxam)
- Atrazine (Atrazine)
- Larvadex (Cyromazine)
- Neporex (Cyromazine)
- Oxyfly (Lambda-cyhalothrin)
- Virusnip (Potassium monopersulfate)
Controversies and criticism
Challenge to India's patent laws
Novartis fought a seven-year, controversial battle to patent Gleevec in India, and took the case all the way to the Indian Supreme Court, where the patent application was finally rejected. The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to abide by worldwide intellectual property standards under the TRIPS agreement. As part of this agreement, India made changes to its patent law; the biggest of which was that prior to these changes, patents on products were not allowed, while afterwards they were, albeit with restrictions. These changes came into effect in 2005, so Novartis' patent application waited in a "mailbox" with others until then, under procedures that India instituted to manage the transition. India also passed certain amendments to its patent law in 2005, just before the laws came into effect, which played a key role in the rejection of the patent application.
The patent application claimed the final form of Gleevec (the beta crystalline form of imatinib mesylate).:3 In 1993, before India allowed patents on products, Novartis had patented imatinib, with salts vaguely specified, in many countries but could not patent it in India. The key differences between the two patent applications were that the 1998 patent application specified the counterion (Gleevec is a specific salt - imatinib mesylate) while the 1993 patent application did not claim any specific salts nor did it mention mesylate, and the 1998 patent application specified the solid form of Gleevec - the way the individual molecules are packed together into a solid when the drug itself is manufactured (this is separate from processes by which the drug itself is formulated into pills or capsules) - while the 1993 patent application did not. The solid form of imatinib mesylate in Gleevec is beta crystalline.
As provided under the TRIPS agreement, Novartis applied for Exclusive Marketing Rights (EMR) for Gleevec from the Indian Patent Office and the EMR was granted in November 2003. Novartis made use of the EMR to obtain orders against some generic manufacturers who had already launched Gleevec in India. Novartis set the price of Gleevec at US$2666 per patient per month; generic companies were selling their versions at US$177 to 266 per patient per month. Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch.
When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy groups. The application was rejected by the patent office and by an appeal board. The key basis for the rejection was the part of Indian patent law that was created by amendment in 2005, describing the patentability of new uses for known drugs and modifications of known drugs. That section, Paragraph 3d, specified that such inventions are patentable only if "they differ significantly in properties with regard to efficacy." At one point, Novartis went to court to try to invalidate Paragraph 3d; it argued that the provision was unconstitutionally vague and that it violated TRIPS. Novartis lost that case and did not appeal. Novartis did appeal the rejection by the patent office to India's Supreme Court, which took the case.
The Supreme Court case hinged on the interpretation of Paragraph 3d. The Supreme Court decided that the substance that Novartis sought to patent was indeed a modification of a known drug (the raw form of imatinib, which was publicly disclosed in the 1993 patent application and in scientific articles), that Novartis did not present evidence of a difference in therapeutic efficacy between the final form of Gleevec and the raw form of imatinib, and that therefore the patent application was properly rejected by the patent office and lower courts.
Although the court ruled narrowly, and took care to note that the subject application was filed during a time of transition in Indian patent law, the decision generated widespread global news coverage and reignited debates on balancing public good with monopolistic pricing, innovation with affordability etc.
Had Novartis won and had its patent issued, it could not have prevented generics companies in India from selling generic Gleevec, but it could have obliged them to pay a reasonable royalty under a grandfather clause included in India's patent law.
In reaction to the decision, Ranjit Shahani, vice-chairman and managing director of Novartis India Ltd was quoted as saying "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options." He also said that companies like Novartis would invest less money in research in India as a result of the ruling. Novartis also emphasised that it continues to be committed to good access to its drugs; according to Novartis, by 2013, "95% of patients in India—roughly 16,000 people—receive Glivec free of charge... and it has provided more than $1.7 billion worth of Glivec to Indian patients in its support program since it was started...."
Sexual discrimination suit
On 17 May 2010, a jury in the United States District Court for the Southern District of New York awarded $3,367,250 in compensatory damages against Novartis, finding that the company had committed sexual discrimination against twelve female sales representatives and entry-level managers since 2002, in matters of pay, promotion, and treatment after learning that the employees were pregnant. Two months later the company settled with the remaining plaintiffs for $152.5 million plus attorney fees.
In September 2008, the US Food and Drug Administration (FDA) sent a notice to Novartis Pharmaceuticals regarding its advertising of Focalin XR, an ADHD drug, in which the company overstated its efficacy while marketing to the public and medical professionals.
In 2005, federal prosecutors opened an investigation into Novartis' marketing of several drugs: Trileptal, an antiseizure drug; three drugs for heart conditions - Diovan (the company's top-selling product), Exforge, and Tekturna; Sandostatin, a drug to treat a growth hormone disorder; and Zelnorm, a drug for irritable bowel syndrome. In September 2010, Novartis agreed to pay US$422.5 million in criminal and civil claims and to enter into a corporate integrity agreement with the US Office of the Inspector General. According to The New York Times, "Federal prosecutors accused Novartis of paying illegal kickbacks to health care professionals through speaker programs, advisory boards, entertainment, travel and meals. But aside from pleading guilty to one misdemeanor charge of mislabeling in an agreement that Novartis announced in February, the company denied wrongdoing." In the same New York Times article, Frank Lichtenberg, a Columbia professor who receives pharmaceutical financing for research on innovation in the industry, said off-label prescribing was encouraged by the American Medical Association and paid for by insurers, but off-label marketing was clearly illegal. "So it's not surprising that they would settle because they don't have a legal leg to stand on."
In April 2013, federal prosecutors filed two lawsuits against Novartis under the False Claims Act for off-label marketing and kickbacks; in both suits, prosecutors are seeking treble damages. The first suit "accused Novartis of inducing pharmacies to switch thousands of kidney transplant patients to its immunosuppressant drug Myfortic in exchange for kickbacks disguised as rebates and discounts". In the second, the Justice Department joined a qui tam, or whistleblower, lawsuit brought by a former sales rep over off-label marketing of three drugs: Lotrel and Valturna (both hypertension drugs), and the diabetes drug, Starlix. Twenty-seven states, the District of Columbia and Chicago and New York also joined.
Fighting off-label prescribing
Outside the US, Novartis markets the drug ranibizumab (trade name Lucentis), which is a monoclonal antibody fragment derived from the same parent mouse antibody as bevacizumab (Avastin). Both Avastin and Lucentis were created by Genentech which is owned by Roche; Roche markets Avastin worldwide, and also markets Lucentis in the US. Lucentis has been approved worldwide as a treatment for wet macular degeneration and other retinal disorders; Avastin is used to treat certain cancers. Because the price of Lucentis is much higher than Avastin, many ophthalmologists began having compounding pharmacies formulate Avastin for administration to the eye, and began treating their patients with Avastin. In 2011, four trusts of the National Health Service in the UK issued policies approving use and payment for administering Avastin for macular degeneration, in order to save money, even though Avastin had not been approved for that indication. In April 2012, after failing to persuade the trusts that it was uncertain whether Avastin was as safe and effective as Lucentis, and in order to retain the market for Lucentis, Novartis announced it would sue the trusts. However, in July Novartis offered significant discounts (kept confidential) to the trusts, and the trusts agreed to change their policy, and in November, Novartis dropped the litigation.
Valsartan data scandal
In the summer of 2013, two Japanese universities retracted several publications of clinical trials that purported to show that Valsartan (branded as Diovan) had cardiovascular benefits, when it was found that statistical analysis had been manipulated, and that a Novartis employee had participated in the statistical analysis but had not disclosed his relationship with Novartis but only his affiliation with Osaka City University, where he was a lecturer.  As a result, several Japanese hospitals stopped using the drug, and media outlets ran reports on the scandal in Japan. In January 2014 Japan's Health Ministry filed a criminal complaint with the Tokyo public prosecutor's office against Novartis and an unspecified number of employees, for allegedly misleading consumers through advertisements that used the research to support the benefits of Diovan. On 1 July 2014 the prosecutor's office announced it was formally charging the company and one of its employees.
Bribery of Greek officials
In January 2018, Novartis began being investigated by Greek authorities for allegedly bribing public officials in the 2006-2015 period. Two former prime ministers, a series of former ministers served in the ministries of health and economy, such as bankers are included in the case, while the current manager of Novartis is banned from leaving the country. The minister's deputy described the allegations as "the biggest scandal since the creation of the Greek state", which caused "annual state expenditure on medicine to explode". Most of the ministers involved in the scandal have denied the allegations, calling the case "political targeting" and "bullying", created by Syriza party. Besides bribery that involves artificial increases in the price of several medicines, the case also involves money laundering, with suspicions of "illegal funds of more than four billion euros ($4.2 billion)" were involved.
Michael Cohen payments
Novartis paid $1.2 million to Essential Consultants, an entity owned by Michael Cohen, following the 2017 inauguration of Donald Trump. Cohen was paid monthly, with each payment just under $100,000. Novartis claims it paid Cohen to help it understand and influence the new administration's approach to drug pricing and regulation.
In July 2018, the US Senate committee report "White House Access for Sale" revealed that Novartis Ag's relationship with Cohen was "longer and more detailed". Novartis initially stated that the relationship ceased a month after entering the US$1.2 million contract with Cohen's consulting firm since the consultants were not able to provide the information the pharmaceutical company needed. Later, it became clear, however, that then-CEO Joseph Jimenez and Cohen communicated via email multiple times during 2017, which included ideas to lower drug prices to be discussed with the president. According to the report, several of the ideas appeared later in Trump's drug pricing plan, released in early 2018, in which pharmaceutical companies were protected from reduced revenues.
AveXis data integrity scandal
Having already received approval for Zolgensma in May 2019, on June 28 AveXis (a Novartis company) voluntarily disclosed to the FDA that some data previously submitted to the agency as part of the Biologics License Application (BLA) package was inaccurate. Specifically, the data manipulation related to an in vivo murine potency assay used in the early development of the product but the issue the FDA and wider community has taken is that AveXis was aware of the data manipulation as early as 14 March 2019, almost two months before the BLA was approved. To compound the problem in early August it emerged a senior manager sold almost $1 million worth of stock immediately before the FDA probe became public on August 6, but after the company had informed the FDA of the problem. As of September 2019 the FDA was still preparing its response to the scandal.
- "Novartis 1Q profit jumps 12 percent as heart drug sales soar". Business. The Seattle Times. Associated Press. 19 April 2018. Retrieved 20 April 2018.
- "Novartis Annual Report 2018" (PDF).
- "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original (PDF) on 16 September 2008. Retrieved 25 August 2008.
- IFPMA Member List Archived 7 February 2014 at the Wayback Machine
- PhRMA Member List Archived 6 October 2013 at the Wayback Machine
- "SEC 2010".
- Roland, Denise. "Novartis Pharmaceuticals Head to Depart Amid Restructuring". WSJ. Retrieved 9 January 2020.
- "Alcon to Officially Spin out From Novartis on April 9". BioSpace. Retrieved 9 January 2020.
- "Novartis Annual Report 2012" (PDF). Novartis. Archived from the original (PDF) on 28 February 2013. Retrieved 6 February 2018.
- "Novartis to split Pharma business unit; names new CEOs". www.thepharmaletter.com. Retrieved 9 January 2020.
- "Novartis AG to Hold On to Its 33% Stake in Roche—For Now". BioSpace. Retrieved 10 January 2020.
- "Avastin vs Lucentis" (PDF).
- "Novartis slashing thousands more jobs in global reorganization, shifting many to India". FiercePharma.
- Staff, EP Vantage. 25 April 2012 Novartis on track to become world's biggest drug maker
- "Novartis Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal | GEN - Genetic Engineering and Biotechnology News". GEN - Genetic Engineering and Biotechnology News. 15 December 2010. Retrieved 14 January 2020.
- "Out From Under Novartis, Alcon Is Its Own Company Now". BioSpace. Retrieved 10 April 2019.
- Reuters, 21 October 2010 Biosimilars take off at Novartis generics unit Archived 20 October 2013 at the Wayback Machine
- Staff, Generics and Biosimilars Initiative, 9 November 2012 Sandoz starts phase III US trial for biosimilar epoetin alfa Archived 20 October 2013 at the Wayback Machine
- "20-F". www.sec.gov. p. 63. Retrieved 11 March 2019.
- Morse, Andrew (11 November 2013). "Novartis Sells Unit for $1.68 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved 21 January 2020.
- "CSL completes Novartis influenza vaccine acquisition in Germany". www.seqirus.com. Retrieved 9 January 2019.
- "GSK Pharma completes acquisition of Novartis Healthcare's vaccines business". Retrieved 21 January 2020.
- "Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV". finance.yahoo.com. Retrieved 11 March 2019.
- Staff and wire reports for the Journal Star (LIncoln, Nebraska) 14 August 2013 Novartis reviews business; analyst urges selling OTC unit
- Staff, WHO. Access to Medicine Index, 2012
- "Novartis AG". Access to Medicine Foundation. Retrieved 22 November 2019.
- Jr, Donald G. McNeil (28 June 2010). "The Drug Industry: GlaxoSmithKline, Merck and Novartis Again Rank Highest on Access to Poor". The New York Times. ISSN 0362-4331. Retrieved 21 January 2020.
- "Novartis AG Revenue 2006-2018 | NVS". www.macrotrends.net. Retrieved 11 March 2019.
- "A history of Novartis -". pharmaphorum.com. 20 September 2013. Retrieved 21 January 2020.
- "Novartis AG | Swiss company". Encyclopedia Britannica. Retrieved 21 January 2020.
- "J R Geigy SA 1857 - 1970".
- "J. R. Geigy Soc. An".
- "Ciba-Geigy AG | Swiss pharmaceutical company". Encyclopedia Britannica. Retrieved 21 January 2020.
- "Company history". Novartis.com. 15 December 2010. Archived from the original on 30 December 2010. Retrieved 2012-01-16.
- "Albert Hofmann, 102, Invented LSD - The New York Sun". Nysun.com. Archived from the original on 20 October 2013. Retrieved 23 October 2013.
- "Patent US2438259 - D-lysergic acid diethyl amide". google.com.
- "Albert Hofmann: LSD - My Problem Child: Use of LSD in Psychiatry". Flashback.se. Archived from the original on 7 July 2006. Retrieved 16 January 2012.
- "Medicine: Dream Stuff". Time. 28 June 1954. Archived from the original on 27 August 2013.
- Anna Bálint: Clariant clareant. The beginnings of a specialty chemicals company, Campus Verlag, Frankfurt am Main/New York 2012, ISBN 978-3-593-39374-2.
- Magnus Grimond for The Independent. 8 March 1996 Ciba-Geigy and Sandoz to merge into pounds 40bn giant Archived 14 December 2013 at the Wayback Machine
- Glenn Collins for The New York Times. 7 March 1996 2 Swiss Drug Giants In a Surprise Merger To Be 2d in World
- Lawrence M. Fisher for strategy + business. 1 April 1998 Post-Merger Integration: How Novartis Became No. 1 Archived 20 May 2013 at the Wayback Machine
- Macilwain, Colin (1 November 1998). "Berkeley teams up with Novartis in $50m plant genomics deal". Nature. 396 (6706): 5. doi:10.1038/23772. ISSN 1476-4687. PMID 9817194.
- Dalton, Rex (1 May 1999). "Berkeley dispute festers over biotech deal". Nature. 399 (6731): 5. doi:10.1038/19807. ISSN 1476-4687.
- Dalton, Rex (1 November 2003). "Syngenta ends plant-research deal with Berkeley". Nature. 426 (6964): 216. doi:10.1038/426216a. ISSN 1476-4687.
- Andrew Ross Sorkin for The New York Times. 3 December 1999 AstraZeneca and Novartis To Shed Agricultural Units Accessed 27 May 2013
- Staff, PRNewsWire. 13 November 2000. Syngenta Begins Trading on the New York Stock Exchange Accessed 27 May 2013[dead link]
- Press Release, Novartis. 21 January 2003 Novartis to Unite Its Generics Businesses Under One Single Global Brand: Sandoz Archived 17 October 2013 at the Wayback Machine
- Emily Church for MarketWatch 21 February 2005 Novartis in $8.29 billion generics deals: to buy Hexal and its US division Eon Labs Archived 20 October 2013 at the Wayback Machine
- Novartis press release. 19 April 2006 Novartis acquisition of Chiron approved by Chiron shareholders Archived 20 October 2013 at the Wayback Machine
- Staff, Biosimilars News. 15 August 2011 Biosimilars approved in Europe Archived 20 October 2013 at the Wayback Machine
- Andrew Martin and Andrew Ross Sorkin for The New York Times. 13 April 2007 Nestlé Agrees to Buy Gerber From Novartis
- Novartis to expand its human vaccines presence in China Archived 13 November 2009 at the Wayback Machine
- Thomasson, Emma (4 January 2010). "Novartis seeks to buy rest of Alcon for $39 billion". Reuters. Archived from the original on 20 October 2013. Retrieved 4 January 2010.
- Novartis Press Release. 8 April 2011 Stronger together: Novartis and Alcon creating the global leader in eye care Archived 20 October 2013 at the Wayback Machine
- "Can Novartis' CEO resist going for a megamerger with cash from asset sales? - FiercePharma". www.fiercepharma.com. Retrieved 6 February 2018.
- Maclucas, Neil (24 January 2011). "Novartis to Buy Genoptix for $470 Million". Health. The Wall Street Journal. Archived from the original on 10 January 2014.
- "Novartis to cut almost 2,000 US jobs this year", The Jakarta Post, Associated Press, jakartapost.com, 13 January 2012, archived from the original on 25 May 2013, retrieved 2012-01-15
- Reid, Katie (13 January 2012), Hans-Juergen Peters and Mike Nesbit (ed.), Novartis cuts 2,000 U.S. jobs after drug setback, Reuters, reuters.com, archived from the original on 10 January 2014, retrieved 2012-01-15
- De la Merced, Michael J. (2 May 2012). "Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion". DealB%k. The New York Times. Retrieved 25 January 2020.
- Harris, Gardiner; Thomas, Katie (1 April 2013). "Top Court in India Rejects Novartis Drug Patent". The New York Times. Retrieved 1 April 2013.
- "US sues Novartis again, says it bribed doctors for patents". Indian Express. Associated Press. Archived from the original on 1 June 2013. Retrieved 29 April 2013. Note: Link provides access to first of two pages; second page is here.
- Staton, Tracy (21 January 2014). "Novartis to cut 500 Swiss pharma jobs, then staff up in OTC, generics". FiercePharma. Questex. Archived from the original on 26 March 2014. Retrieved 19 February 2014.
- Johnson, Michael (18 January 2014). "Novartis acquires CoStim Pharmaceuticals". Drug Store News. Lebhar-Friedman. Archived from the original on 25 February 2014. Retrieved 19 February 2014.
- Staff (15 June 2014). "Novartis Buys Ex-U.S. Rights to Ophthotech's Fovista for Up to $1B". News | Industry Watch. Genetic Engineering & Biotechnology News (Paper). 34 (12). Mary Ann Liebert. p. 8. Retrieved 25 January 2020.
- Staff (8 September 2014). "Ophthotech Pockets $50M Milestone from Novartis for AMD Treatment". GEN News Highlights. Genetic Engineering & Biotechnology News. Mary Ann Liebert. Retrieved 14 September 2014.
- BBC (22 April 2014). "Novartis and GSK exchange assets". BBC. Archived from the original on 29 April 2014. Retrieved 22 April 2014.
- "Novartis Takes Stake in Gamida with Option to Fully Buy". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 19 August 2014. Retrieved 25 January 2020.
- "Novartis Selling Flu Vaccine Business to CSL for $275M". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 27 October 2014. Retrieved 25 January 2020.
- "Array BioPharma Completes Deal with Novartis for 2 Cancer Compounds". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 2 March 2015. Retrieved 25 January 2020.
- "Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". GEN News Highlights. Genetic Engineering & Biotechnology News. Mary Ann Liebert. 5 March 2015. Archived from the original on 9 April 2015. Retrieved 8 June 2016. Note: appears on page 10 of 1 April 2015 print issue.
- "Novartis Acquires Spinifex for $200M+". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 29 June 2015. Retrieved 25 January 2020.
- Helfand, Cindy (21 August 2015). "Novartis shells out up to $1B to test GSK's Arzerra in MS". FiercePharma. Questex. Retrieved 25 January 2020.
- "Novartis Acquires All Remaining Rights to GSK's Ofatumumab". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 21 August 2015. Archived from the original on 23 August 2015.
- "Novartis Buys Admune; Licenses Palobiofarma, XOMA Compounds". Genetic Engineering & Biotechnology News. Mary Ann Liebert. 21 October 2015. Retrieved 25 January 2020.
- "Novartis Acquires Selexys Pharmaceuticals - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". 21 November 2016.
- "Novartis Buys Encore Vision for Presbyopia Therapy Eyedrops - GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business - GEN". 20 December 2016.
- Terry, Mark (19 December 2016). "Novartis AG Snaps Up Mid-Stage Eczema Rival". BioSpace.
- Editorial, Reuters (3 November 2017). "Novartis to buy French cancer specialist AAA for $3.9 billion". Reuters. Retrieved 6 February 2018.
- "GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business | GSK". www.gsk.com. 27 March 2018.
- "GSK buys out Novartis in $13 billion consumer healthcare shake-up". Reuters. 27 March 2018.
- "Novartis bets big on gene therapy with $8.7 billion AveXis deal". Reuters. 9 April 2018.
- "Novartis licenses out unwanted GlaxoSmithKline cancer drugs to Chinese biotech | FierceBiotech". www.fiercebiotech.com. Retrieved 3 August 2018.
- "China's Laekna Inks Two-Drug Deal with Novartis | BioSpace". BioSpace. Retrieved 3 August 2018.
- "Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash". Reuters. 18 October 2018.
- "Novartis pushes deeper into nuclear medicine with $2.1 billion deal". Reuters. 18 October 2018.
- "Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms". Novartis. 18 October 2018.
- "Novartis to buy France's CellforCure to boost cell, gene therapy". Reuters. 20 December 2018.
- Neville, Sarah; Waters, Richard. "Novartis and Microsoft join forces to develop drugs using AI". Financial Times. Retrieved 5 November 2019.
- Terry, Mark (25 November 2019). "Novartis Buys The Medicines Company: A $9.7 Billion Gamble on a PCSK9 Cholesterol Drug". BioSpace. Urbandale, Iowa. Retrieved 1 December 2019.
- "Novartis set to buy Medicines Co. for $9.7 billion". Leaders League. Paris. 26 November 2019. Retrieved 1 December 2019.
- Ross, Casey (27 October 2010). "Novartis doubles plan for Cambridge". The Boston Globe. Archived from the original on 3 November 2012. Retrieved 31 October 2010.
- Novartis Institutes for BioMedical Research Official SIte Archived 2 May 2014 at the Wayback Machine
- Innovation for the developing world Archived 9 February 2014 at the Wayback Machine
- Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
- InnoMed PredTox Member Organizations (web page), InnoMed, archived from the original on 26 September 2008, retrieved 25 August 2008
- Innovative Medicines Initiative, ed. (2008), "IMI-GB-018v2-24042008-CallTopics.pdf", IMI 1st Call 2008: Information Package (ZIP archive), European Commission, archived from the original (PDF) on 24 September 2015, retrieved 16 January 2012
- "Novartis, U.S. partner plan remote trials to boost participation". Reuters. 7 March 2018. Retrieved 15 March 2018.
- Novartis Top 20 Products Annual Sales (Novartis Website), accessed 19 October 2013 Archived 28 April 2014 at the Wayback Machine
- Teva press release. 30 January 2007 Teva Receives Approval for Generic Focalin™ Tablets
- "IPCI: FDA Approves First Focalin XR ANDA; Positive Incremental Step Toward Approval and October Launch for IPCI". Archived from the original on 20 October 2013.
- Novartis official 2007 product sales From Internet Archive; archive date 13 November 2007
- Commissioner, Office of the (11 September 2019). "FDA approves new oral drug to treat multiple sclerosis". FDA. Retrieved 16 October 2019.
- "Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease". Novartis. Retrieved 16 October 2019.
- "Sertraline Sandoz Tablet". NPS MedicineWise. Retrieved 9 January 2019.
- EMEA Approval for Pasireotide Archived 4 February 2014 at the Wayback Machine
- "FDA Approves Pasireotide for Cushing's Disease". Archived from the original on 30 July 2013.
- "NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel", The Wall Street Journal, online.wsj.com, 12 January 2012, archived from the original on 17 May 2013, retrieved 2012-01-15
- Teva press release. 14 October 2013 Teva Announces FDA Approval of Generic TOBI® in the United States
- Teva Press Release 12 December 2007 Teva Announces Approval of Generic Trileptal Tablets Archived 20 October 2013 at the Wayback Machine
- "US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine" (Press release). Novartis. 15 January 2009. Archived from the original on 3 June 2010. Retrieved 13 November 2009.
- Staton, Tracy (22 April 2014). "Novartis, GSK team up in consumer JV to save big money, gain big scale". FiercePharma. Questex Media Group. Retrieved 16 May 2016.
- Note: The Indian patent application No.1602/MAS/1998 does not appear to be publicly available. However according to the decision of the IPAB on 26 June 2009 (page 27) discussed below, "The Appellant's application under the PCT was substantially on the same invention as had been made in India." Archived 22 October 2013 at the Wayback Machine
- Published PCT application WO1999003854 Archived 22 October 2013 at the Wayback Machine
- Staff, European Medicines Agency, 2004. EMEA Scientific Discussion of Glivec
- "Patent US5521184 - Pyrimidine derivatives and processes for the preparation thereof". google.com.
- Indian Supreme Court Decision paragraphs 5-6 Archived 6 July 2013 at the Wayback Machine
- Novartis v UoI, para 8-9 Archived 6 July 2013 at the Wayback Machine
- Shamnad Basheer for Spicy IP 11 March 2006 First Mailbox Opposition (Gleevec) Decided in India Archived 21 October 2013 at the Wayback Machine
- Staff, LawyersCollective. 6 September 2011 Novartis case: background and update – Supreme Court of India to recommence hearing Archived 21 October 2013 at the Wayback Machine
- R. Jai Krishna and Jeanne Whalen for The Wall Street Journal. 1 April 2013 Novartis Loses Glivec Patent Battle in India
- Intellectual Property Appellate Board decision dated 26 June 2009, p 149 Archived 22 October 2013 at the Wayback Machine
- W.P. No.24759 of 2006 Archived 20 October 2013 at the Wayback Machine
- "Supreme Court rejects bid by Novartis to patent Glivec". Archived from the original on 17 December 2013.
- Novartis v UoI, Para 191 Archived 6 July 2013 at the Wayback Machine
- Novartis v UoI, Para 24-25 Archived 6 July 2013 at the Wayback Machine
- "How the Indian judgment will reverberate across the world". Archived from the original on 18 January 2014.
- "Patented drugs must be priced smartly". Archived from the original on 20 October 2013.
- Patent with a purpose, Prof. Shamnad Basheer, Indian Express, 3 April 2013 Archived 26 May 2013 at the Wayback Machine
- Kevin Grogan for PharmaTimes. 27 February 2012 Novartis explains stance over India patent law challenge Archived 16 December 2014 at the Wayback Machine
- Erklärung von Bern. 8 May 2007 Short questions and answers about the court case initiated by Novartis in India Archived 21 October 2013 at the Wayback Machine
- Shift in Novartis Strategy, The Telegraph Archived 11 May 2013 at the Wayback Machine
- "Novartis Reaches $152.5 Million Sex-Bias Settlement".
- "Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules CII". Warning Letters. US Food and Drug Administration. 25 September 2008. Archived from the original on 10 February 2012. Retrieved 2009-08-05.
- Wilson, Duff (30 September 2010). "Novartis Settles Off-Label Marketing Case". NYTimes.com. Retrieved 16 January 2012.
- "Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office" (press release). Novartis. 30 September 2010. Media Releases. Archived from the original on 17 October 2013. Retrieved 16 January 2012.
- "U.S. Sues Novartis Again, Accusing It of Kickbacks". The New York Times. 26 April 2013. Retrieved 27 April 2013.
- "United States Files Complaint Against Novartis Pharmaceuticals Corp. for Allegedly Paying Kickbacks to Doctors in Exchange for Prescribing Its Drugs". The United States Department of Justice. 26 April 2013. Archived from the original on 13 April 2014. Retrieved 26 April 2013.
- Andrew Pollack for The New York Times. 28 April 2011 Cheaper Drug to Treat Eye Disease Is Effective
- Jeffreys, Branwen (6 May 2012). "Using Avastin for eye condition wet AMD 'could save NHS £84m'". bbc.com. Archived from the original on 6 November 2013. Retrieved 6 May 2012.
- Copley, Caroline; Hirschler, Ben (24 April 2012), Potter, Mark (ed.), Novartis challenges UK Avastin use in eye disease, Reuters, archived from the original on 22 May 2013, retrieved 2012-04-29
- Ben Adams for Pharmafile. 26 July 2012 Lucentis price cut ends PCT-Novartis dispute Archived 19 October 2013 at the Wayback Machine
- Ben Adams for Pharma Times. 3 October 2012. Novartis to drop legal case against NHS body Archived 19 October 2013 at the Wayback Machine
- Kana Inagaki for The Wall Street Journal. 11 August 2013 Novartis Hit by Scandal Over Japanese Drug Studies: Probes Uncover Altered Research Data; Swiss Giant Stands by Heart Medicine Diovan Archived 13 October 2013 at the Wayback Machine
- Kana Inagaki for The Wall Street Journal. 12 August 2013. Novartis Drug Studies in Japan–Tracing Back the Questions Archived 18 October 2013 at the Wayback Machine
- "Japan Criminal Probe Could Spell More Trouble for Novartis". The Wall Street Journal. 10 January 2014. Archived from the original on 2 March 2014.
- "Data manipulation by staff gets Novartis into legal mess in Japan". Japan Herald. Archived from the original on 29 August 2014. Retrieved 2 July 2014.
- "Greek Officials Hit Back at Novartis Bribery Allegations | GreekReporter.com". greece.greekreporter.com. Retrieved 7 February 2018.
- "Greek officials ban Novartis manager from leaving the country amid widening bribery probe: report | FiercePharma". www.fiercepharma.com. Retrieved 7 February 2018.
- Press, The Associated (5 February 2018). "Greek Govt Alleges Official Ties to Drug Bribery Scandal". The New York Times. ISSN 0362-4331. Retrieved 7 February 2018.
- (www.dw.com), Deutsche Welle. "Novartis under investigation for bribery in Greece | Europe| News and current affairs from around the continent | DW | 22.01.2017". DW.COM. Retrieved 7 February 2018.
- "Novartis admits $1.2m in payments to Trump lawyer". Financial Times. Retrieved 10 May 2018.
- Emma Court (16 July 2018.) Novartis had 'longer and more detailed' relationship with Trump lawyer Michael Cohen, Senate report finds. MarketWatch. Retrieved 21 August 2018.
- White House Access for Sale: Michael Cohen, Novartis and the bid to sell access to the Trump administration. Retrieved 21 August 2018.
- Kirkland, Rik; Jimenez, Joseph (June 2015). "Novartis on digitizing medicine in an aging world". Insights & Publications (Interview). McKinsey & Company. Retrieved 16 August 2015.
|Wikimedia Commons has media related to Novartis.|